We exist to make childbirth safe for mothers and babies

A breakthrough in childbirth care and a proud moment for the VitalTrace team. Our continuous lactate monitor for childbirth, DelivAssure, has been featured on a number of media platforms, including the ABC, as a potential breakthrough.

‍Full ABC News feature here
‍

A moment of thanks on the achievement of the recent clinical trials:

We want to especially thank our Chief Medical Officer Jonathan Morris, the tireless Sharon McCracken, and our long-time collaborator Jane Pillow, who have been integral to our progress.

Thank you to our Principal Investigators across our clinical trials: A/Professor Sean Seeho, Penny Sheehan, Daniel Rolnik and Scott White. We’re incredibly grateful to the clinical teams and hospitals who made these trials possible across Royal North Shore Hospital, Monash Health, King Edward Memorial Hospital and Box Hill Hospital - Eastern Health.

The mothers and babies who took part in our trials are also at the heart of our work. We are endlessly appreciative for their participation.

Also with thanks to our partners and supporters: The University of Western Australia, University of Sydney, University of Technology Sydney, Australian Government and Government of Western Australia's Future Health Research and Innovation (FHRI) and Department of Jobs, Tourism, Science and Innovation (JTSI), Fund WA and Artesian (Alternative Investments).

Most of all, a huge thank you to our entire VitalTrace team whose hard work and dedication everyday have lead to this outcome.

Our first peer-reviewed journal article has been published in The SMFM Pregnancy Journal — the official open-access journal of the Society for Maternal-Fetal Medicine (SMFM) based in Washington, DC.

In collaboration with The University of Western Australia, our study demonstrates the capability of our technology, DelivAssure, in detecting early signs of fetal lactic acidosis, highlighted by the strong correlation between sensor current and venous blood lactate levels.  

We're proud to contribute to the growing body of evidence aimed at improving outcomes for mothers and babies — DelivAssure has the potential to revolutionise intrapartum care by enabling crucial early detection and management of fetal asphyxia during labor and delivery.

📰 Read the full article here: https://onlinelibrary.wiley.com/doi/10.1002/pmf2.70017

We're incredibly grateful to our collaborators, clinical partners, and the SMFM editorial team for supporting this work.

VitalTrace has officially commenced its participation in the Texas Medical Center Innovation (TMCi) 2025 HealthTech Accelerator. Out of over 120 global applicants, we are proud to be one of just 12 companies selected—and among a very small number of international participants.

TMC is the largest healthcare provider in the United States and one of the largest globally. This opportunity has already yielded significant gains for the company, deepening our understanding of the U.S. hospital landscape. Discussions with leading institutions highlighted a consistent drive to reduce caesarean section rates, driven by strong fiscal and clinical imperatives.

Obstetricians and healthcare executives were candid in their support, emphasizing the urgent need for improved diagnostic tools. They shared that legal settlements related to hypoxic-ischemic encephalopathy can exceed US$40 million in Texas—and even higher in states like Massachusetts—underscoring the critical importance of innovation in this space.

We are immensely proud of the team’s efforts in preparing the company for this milestone, and we are deeply encouraged by the warm and validating reception we received in the U.S. We look forward to continuing our participation and contributing meaningfully to the program.